Zhejiang East Crystal Electronic Co.,Ltd. (002199.SZ)
CNY 12.32
(1.32%)
CNY 12.32
(1.32%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.61 Million | -32.51 Million | 44.63 Million | 24.48 Million | 11.19 Million | 18.28 Million |
| Net Income | -66.59 Million | -69.31 Million | 30.84 Million | 7.97 Million | 14.79 Million | -78.62 Million |
| Depreciation & Amortization | 37.27 Million | 31.1 Million | 30.63 Million | 24.3 Million | 23.06 Million | 40.13 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -14.58 Million | -46.27 Million | -19.08 Million | -16.04 Million | -14.78 Million | -6.16 Million |
| Other non-cash items | 39.29 Million | 51.97 Million | 2.23 Million | 8.23 Million | -11.87 Million | 62.94 Million |
| Investing Cash Flow | -15.05 Million | -80.64 Million | -50.09 Million | -40.13 Million | 63.68 Million | -19.3 Million |
| Investments in PPE | -14.43 Million | -80.67 Million | -57.48 Million | -45.64 Million | -48 Million | -70 Million |
| Acquisitions | - | 32.89 Thousand | 7.4 Million | 50.82 Million | 116.54 Million | - |
| Investment purchases | -617.71 Thousand | - | -1 Million | -34 Million | -178.32 Million | -42.98 Million |
| Sales/Maturities of investments | 10.5 Thousand | - | 1.96 Million | 34.32 Million | 180.47 Million | 42.86 Million |
| Other Investing Activities | -10.5 Thousand | 32.89 Thousand | -979.99 Thousand | -45.64 Million | -6.99 Million | 50.82 Million |
| Financing Cash Flow | 40.87 Million | -339.1 Thousand | 54.75 Million | -259.12 Thousand | -263.7 Thousand | -268.29 Thousand |
| Debt repayment | -47.78 Million | -15 Million | -60 Million | -254.54 Thousand | -254.54 Thousand | -254.54 Thousand |
| Dividends payments | -3.66 Million | -2.78 Million | -822.55 Thousand | -4581.82 | -9163.64 | -13.74 Thousand |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -3.66 Million | 17.44 Million | 115.57 Million | -4581.82 | -254.54 Thousand | - |
| Accounts receivables | 12.82 Million | 29.46 Million | -21.77 Million | -31.43 Million | -22.18 Million | -23.3 Million |
| Accounts payables | -18.84 Million | -41.55 Million | 21.77 Million | 31.43 Million | 22.18 Million | - |
| Inventory | -10.51 Million | -34.18 Million | -32.97 Million | -8.72 Million | -15.63 Million | -11.95 Million |
| Other working capital | 1.94 Million | 0.46 | 13.89 Million | -7.31 Million | 850.65 Thousand | 5.78 Million |
| Cash at beginning of period | 42.19 Million | 148.96 Million | 99.67 Million | 115.58 Million | 40.97 Million | 42.25 Million |
| Cash at end of period | 56.68 Million | 35.47 Million | 148.96 Million | 99.67 Million | 115.58 Million | 40.97 Million |
| Capital Expenditure | -14.43 Million | -80.67 Million | -57.48 Million | -45.64 Million | -48 Million | -70 Million |
| Effect of forex changes on cash | -224.82 | - | - | 0.69 | 1.09 | - |
| Net cash flow / Change in cash | 14.48 Million | -113.49 Million | 49.29 Million | -15.91 Million | 74.61 Million | -1.28 Million |
| Free Cash Flow | -19.04 Million | -113.19 Million | -12.85 Million | -21.16 Million | -36.81 Million | -51.71 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | -15.54 Million | -17.76 Million | -66.59 Million | -22.89 Million | -18.24 Million |
| Depreciation & Amortization | - | 10.34 Million | 10.34 Million | 37.27 Million | 9.56 Million | -17.31 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | -14.58 Million | 4.25 Million | -15.09 Million |
| Other non-cash items | - | 18.42 Million | 19.89 Million | 39.29 Million | 8.13 Million | 50.09 Million |
| Investing Cash Flow | -89.85 Thousand | -1.15 Million | -167.13 Thousand | -15.05 Million | -3.28 Million | -1.78 Million |
| Investments in PPE | -89.85 Thousand | -1.15 Million | -167.13 Thousand | -14.43 Million | -2.67 Million | -1.78 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | -617.71 Thousand | -617.71 Thousand | - |
| Sales/Maturities of investments | - | - | 85 Thousand | 10.5 Thousand | - | - |
| Other Investing Activities | - | - | 85 Thousand | -10.5 Thousand | -617.71 Thousand | - |
| Financing Cash Flow | -1.77 Million | -6.86 Million | -3.6 Million | 40.87 Million | 13.41 Million | 20.33 Million |
| Debt repayment | - | -5 Million | -2 Million | -47.78 Million | -15 Million | -15 Million |
| Dividends payments | -1.04 Million | -1.13 Million | -1.07 Million | -3.66 Million | -1.04 Million | -974.43 Thousand |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -723.42 Thousand | -722.7 Thousand | -1.6 Million | -3.66 Million | 1.65 Million | 36.31 Million |
| Accounts receivables | - | - | - | 12.82 Million | 12.82 Million | -14.76 Million |
| Accounts payables | - | - | - | -18.84 Million | - | - |
| Inventory | - | - | - | -10.51 Million | -10.51 Million | -330.82 Thousand |
| Other working capital | - | - | - | 1.94 Million | 1.94 Million | - |
| Cash at beginning of period | 39.56 Million | 55.03 Million | 56.68 Million | 42.19 Million | 47.49 Million | 29.5 Million |
| Cash at end of period | 41.25 Million | 39.56 Million | 55.03 Million | 56.68 Million | 56.68 Million | 47.49 Million |
| Capital Expenditure | -89.85 Thousand | -1.15 Million | -167.13 Thousand | -14.43 Million | -2.67 Million | -1.78 Million |
| Effect of forex changes on cash | -3658.22 | 2133.59 | -6213.29 | -224.82 | 292.42 | -517.00 |
| Net cash flow / Change in cash | 1.69 Million | -15.47 Million | -1.64 Million | 14.48 Million | 9.18 Million | 17.99 Million |
| Free Cash Flow | -89.85 Thousand | -8.61 Million | 1.96 Million | -19.04 Million | -3.6 Million | -2.34 Million |
VIZC
CSTAF
ISOLF
SPNS
BIOCQ
ASND